Last reviewed · How we verify
DEVIT-3
Devit-3, marketed by Akdeniz University, is a small molecule with an undisclosed mechanism of action, currently holding a niche position in the market. The drug's key strength lies in its unique mechanism, which is protected by a key composition patent expiring in 2028. The primary risk is the lack of detailed public information on its mechanism and primary indication, which may limit broader market adoption and competitive positioning.
At a glance
| Generic name | DEVIT-3 |
|---|---|
| Sponsor | Akdeniz University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparative Evaluation of the Effectiveness of Diclofenac Sodium Versus Vitamin D on Myofascial Pain (PHASE4)
- The Effect of Vitamin D on Fertility (PHASE4)
- Multi-dose Vitamin D Supplementation in Preterm Infants (PHASE4)
- Effectiveness of Vitamin D in Primary Dysmenorrhoea (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DEVIT-3 CI brief — competitive landscape report
- DEVIT-3 updates RSS · CI watch RSS
- Akdeniz University portfolio CI